Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carfilzomib-based Chemotherapy Mobilization for ASCT in Multiple Myeloma
NCT03909412Phase 1Recruiting
- Sponsor
- Hackensack Meridian Health
- Start
- Oct 2019
- Primary completion
- Aug 2027
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label trial of carfilzomib in multiple myeloma (MM) (6 arms), sponsored by Hackensack Meridian Health. Primary endpoints: Number of participants with treatment-related adverse events at 24 months and Maximum tolerated dose at 28 days. Started Oct 2019; status: recruiting.
02
Drugs
carfilzomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03909412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03909412.